Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis

Sujata Sundara Rajan, Veronica L. Cavera, Xiaoping Zhang, Yashveer Singh, Michael Chikindas, Patrick Sinko

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current treatment options for bacterial vaginosis (BV) have been shown to be inadequate at preventing recurrence and do not provide protection against associated infections, such as that with HIV. This study examines the feasibility of incorporating the antimicrobial peptide subtilosin within covalently cross-linked polyethylene glycol (PEG)-based hydrogels for vaginal administration. The PEG-based hydrogels (4% and 6% [wt/vol]) provided a two-phase release of subtilosin, with an initial rapid release rate of 4.0 μg/h (0 to 12 h) followed by a slow, sustained release rate of 0.26 μg/h (12 to 120 h). The subtilosin-containing hydrogels inhibited the growth of the major BV-Associated pathogen Gardnerella vaginalis with a reduction of 8 log10 CFU/ml with hydrogels containing≥15 μg entrapped subtilosin. In addition, the growth of four common species of vaginal lactobacilli was not significantly inhibited in the presence of the subtilosin-containing hydrogels. The above findings demonstrate the potential application of vaginal subtilosin-containing hydrogels for prophylaxis of BV.

Original languageEnglish (US)
Pages (from-to)2747-2753
Number of pages7
JournalAntimicrobial agents and chemotherapy
Volume58
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bacterial Vaginosis
Hydrogels
Intravaginal Administration
Gardnerella vaginalis
Feasibility Studies
Lactobacillus
Growth
Bacillus subtilis sboA protein
HIV
Recurrence
Peptides
Infection

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{e34279bf03e44bd4b89e0e00d05b6995,
title = "Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis",
abstract = "Current treatment options for bacterial vaginosis (BV) have been shown to be inadequate at preventing recurrence and do not provide protection against associated infections, such as that with HIV. This study examines the feasibility of incorporating the antimicrobial peptide subtilosin within covalently cross-linked polyethylene glycol (PEG)-based hydrogels for vaginal administration. The PEG-based hydrogels (4{\%} and 6{\%} [wt/vol]) provided a two-phase release of subtilosin, with an initial rapid release rate of 4.0 μg/h (0 to 12 h) followed by a slow, sustained release rate of 0.26 μg/h (12 to 120 h). The subtilosin-containing hydrogels inhibited the growth of the major BV-Associated pathogen Gardnerella vaginalis with a reduction of 8 log10 CFU/ml with hydrogels containing≥15 μg entrapped subtilosin. In addition, the growth of four common species of vaginal lactobacilli was not significantly inhibited in the presence of the subtilosin-containing hydrogels. The above findings demonstrate the potential application of vaginal subtilosin-containing hydrogels for prophylaxis of BV.",
author = "Rajan, {Sujata Sundara} and Cavera, {Veronica L.} and Xiaoping Zhang and Yashveer Singh and Michael Chikindas and Patrick Sinko",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.02446-14",
language = "English (US)",
volume = "58",
pages = "2747--2753",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis. / Rajan, Sujata Sundara; Cavera, Veronica L.; Zhang, Xiaoping; Singh, Yashveer; Chikindas, Michael; Sinko, Patrick.

In: Antimicrobial agents and chemotherapy, Vol. 58, No. 5, 01.01.2014, p. 2747-2753.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis

AU - Rajan, Sujata Sundara

AU - Cavera, Veronica L.

AU - Zhang, Xiaoping

AU - Singh, Yashveer

AU - Chikindas, Michael

AU - Sinko, Patrick

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Current treatment options for bacterial vaginosis (BV) have been shown to be inadequate at preventing recurrence and do not provide protection against associated infections, such as that with HIV. This study examines the feasibility of incorporating the antimicrobial peptide subtilosin within covalently cross-linked polyethylene glycol (PEG)-based hydrogels for vaginal administration. The PEG-based hydrogels (4% and 6% [wt/vol]) provided a two-phase release of subtilosin, with an initial rapid release rate of 4.0 μg/h (0 to 12 h) followed by a slow, sustained release rate of 0.26 μg/h (12 to 120 h). The subtilosin-containing hydrogels inhibited the growth of the major BV-Associated pathogen Gardnerella vaginalis with a reduction of 8 log10 CFU/ml with hydrogels containing≥15 μg entrapped subtilosin. In addition, the growth of four common species of vaginal lactobacilli was not significantly inhibited in the presence of the subtilosin-containing hydrogels. The above findings demonstrate the potential application of vaginal subtilosin-containing hydrogels for prophylaxis of BV.

AB - Current treatment options for bacterial vaginosis (BV) have been shown to be inadequate at preventing recurrence and do not provide protection against associated infections, such as that with HIV. This study examines the feasibility of incorporating the antimicrobial peptide subtilosin within covalently cross-linked polyethylene glycol (PEG)-based hydrogels for vaginal administration. The PEG-based hydrogels (4% and 6% [wt/vol]) provided a two-phase release of subtilosin, with an initial rapid release rate of 4.0 μg/h (0 to 12 h) followed by a slow, sustained release rate of 0.26 μg/h (12 to 120 h). The subtilosin-containing hydrogels inhibited the growth of the major BV-Associated pathogen Gardnerella vaginalis with a reduction of 8 log10 CFU/ml with hydrogels containing≥15 μg entrapped subtilosin. In addition, the growth of four common species of vaginal lactobacilli was not significantly inhibited in the presence of the subtilosin-containing hydrogels. The above findings demonstrate the potential application of vaginal subtilosin-containing hydrogels for prophylaxis of BV.

UR - http://www.scopus.com/inward/record.url?scp=84898609021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898609021&partnerID=8YFLogxK

U2 - 10.1128/AAC.02446-14

DO - 10.1128/AAC.02446-14

M3 - Article

C2 - 24566190

AN - SCOPUS:84898609021

VL - 58

SP - 2747

EP - 2753

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -